Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Summary
This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-08-26
- Completion
- 2028-01-01
Outcome
Met primary endpoint
paper Lorazepam + haloperidol resulted in a significantly greater reduction of RASS score at 8 hours (-4.1 points) than placebo + haloperidol (-2.3 points) PMID 28975307 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorazepam | Small molecule | 3 mg | Intravenous |
| Background | Haloperidol Decanoate | Small molecule | 8 mg | Intravenous |